Robert W. Baird analyst Vikram Kesavabhotla maintained a Buy rating on InnovAge Holding (INNV – Research Report) on February 13 and set a price target of $6.00. The company’s shares closed last Wednesday at $4.98, close to its 52-week low of $3.46.
According to TipRanks.com, Kesavabhotla is ranked 0 out of 5 stars with an average return of -12.7% and a 38.3% success rate. Kesavabhotla covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, GoodRx Holdings, and SOC Telemed.
The word on The Street in general, suggests a Hold analyst consensus rating for InnovAge Holding with a $5.00 average price target.
See the top stocks recommended by analysts >>
Based on InnovAge Holding’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $173 million and net profit of $7.69 million. In comparison, last year the company earned revenue of $157 million and had a net profit of $9.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes.
Read More on INNV:
- EMS-CHEMIE HOLDING AG (EMSHF) Gets a Buy Rating from Berenberg Bank
- Robert W. Baird Remains a Buy on Wyndham Hotels & Resorts (WH)
- Robert W. Baird Believes Hilton Worldwide Holdings (HLT) Won’t Stop Here
- Mizuho Securities Sticks to Their Hold Rating for VMware (VMW)
- Mizuho Securities Keeps Their Hold Rating on Splunk (SPLK)
